Graham Higson joins NDA Group to lead Regulatory and HTA Advisory Board

pharmafile | November 4, 2011 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NDA 

GE Healthcare and ex AstraZeneca Head of Global Regulatory Affairs, Graham Higson, will join NDA Group in January 2012 to lead its Regulatory Affairs and HTA Advisory Board. 

Higson will lead an Advisory Board of prominent ex-members of EU regulatory committees and industry experts located across Europe.

As managing director of NDA Advisory Services Ltd, Higson’s goal is to drive greater regulatory and HTA alignment for pharmaceutical companies globally.

Higson joins NDA from the Medical Diagnostics division of GE Healthcare, where he spent the past year as head of global regulatory affairs. During his time there, Higson held a critical leadership role that was instrumental in steering regulatory excellence worldwide and he also played a key role in driving the future vision of R&D.

“I believe Graham’s extensive knowledge and experience, coupled with his in-depth insight into the challenges pharmaceutical companies face in fulfilling new drug development plans, right through to the real-life requirements of HTA, will prove invaluable to our clients and to our expert Advisory Board,” said Dr. Lars-Helge Strömquist, CEO, NDA Group.  

Higson succeeds the former head of the Regulatory Advisory Board, Dave Gilbert, who retires as managing director later this year. Gilbert will continue to provide advice to NDA’s clients on a part time basis as a regular member of the Advisory Board. Higson joins NDA on 1st January 2012 and will be based in the UK.

Related Content

FDA accepts NDA for Karuna’s schizophrenia treatment

Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its …

FDA accepts Sun Pharma’s NDA for deuruxolitinib

India-based pharma company Sun Pharmaceutical Industries has announced that the US Food and Drug Administration …

Bristol Myers Squibb’s NDA accepted by FDA

Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) …

Latest content